Article

Femtosecond-only laser vision correction available outside U.S.

The first femtosecond-only method of laser vision correction is now able to be performed outside the United States after several years of clinical research and development, according to the manufacturer of the laser with which it is performed (VisuMax, Carl Zeiss Meditec).

Dublin, CA

-The first femtosecond-only method of laser vision correction is now able to be performed outside the United States after several years of clinical research and development, according to the manufacturer of the laser with which it is performed (VisuMax, Carl Zeiss Meditec).

“Because the entire procedure can be performed on one advanced system, we are able to deliver unprecedented workflow benefits to the practice,” said Ludwin Monz, chief executive officer of Carl Zeiss Meditec. “We believe that providing refractive surgeons with a range of flexible treatment approaches allows them to select the most appropriate set of technologies for their surgical settings.”

Collectively, the company refers to two procedures (Femtosecond Lamellar Extraction, or FLEx, and Small Incision Lamellar Extraction, or SMILE) by a brand name (ReLEx). The methods use laser cutting, as opposed to tissue ablation, and allow for flap sizes 0.5 to 1 mm larger in diameter than the optical zone. To date, the procedures have been performed on more than 1,000 eyes at a variety of locations outside of the United States.

The femtosecond laser used to perform these procedures is available for sale in the United States for the creation of a corneal flap in patients undergoing LASIK surgery or other treatment requiring lamellar resection of the cornea.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.